Abstract Patient-initiated repackaging of antiretroviral therapy (ART) refers to removal of ART medications from their original manufacturer's containers, and putting them into alternative containers. This behavior may be triggered by stigma associated with HIV infection, and may impact patient outcomes. We assessed association between patient initiated repackaging of ART and failure to achieve viral suppression (FVS) in a sample of 450 HIV-infected adults (C8 years) on first line ART for C6 months. FVS was defined as a plasma HIV RNA level C400 copies/mL. A total of 197 (43.7%) patients reported repackaging their ART medications. One hundred ninety-one patients (42.4%) failed to suppress and FVS was associated with medication repackaging [adjusted odds ratio (aOR), 2.2; 95% CI 1.4-3.3.] Adherence to ART was also associated with FVS (aOR; 0.4; 95% CI 0.2-0.6.). Benefits of retaining drugs in their original packaging along with adherence to ART should be emphasized to reduce the risk of FVS.
Introduction
Despite the benefits associated with manufacturer's original packaging, patient-initiated repackaging of antiretroviral therapy (ART) has been reported in several studies in sub Saharan Africa studies [1] [2] [3] . Patient-initiated repackaging of ART refers to removal of ART from their original manufacturer's containers, and putting them into alternative containers such as paper or plastic bags, other pill bottles or other containers. Unlike adherence aids, which are intended to simplify patient's complex and confusing medication regimen [4] and improving medication adherence [5] , patients-initiated repackaging may have negative consequences if related to underlying stigma associated with HIV infection.
The main benefit of manufacturer's original packaging is protection of drug effectivity [4, 6] . Alternative repackaging materials may compromise medication effectivity especially if the storage conditions are not ideal. For example, exposure to varied temperature ranges and moisture [4] .If the alternative packaging does not contain desiccants, medication may absorb moisture, potentially impairing the drug's effectivity. Moreover, patients are likely to mix up their tablets, lose or forget timing of taking them as package inserts are likely to be lost with alternative packaging. In previous study, factors such as convenience of carrying multiple pills and HIV-associated stigma have been found to be associated patient-initiated repackaging of ART [3] . Since HIV-related stigma is associated with poor patient outcomes [7] [8] [9] , it is possible that patients who repackage their ART may be less likely to take their medications appropriately which may lead to failure to achieve viral suppression. While there are studies that explored reasons for repackaging of medications, those that evaluate association of repackaging and health outcomes such as viral suppression in the context of HIV are lacking. Understanding the association between viral suppression and medication repackaging is critical in order to implement intervention to halt this behavior and conserve drugs effectivity.
The objective of these analyses is to evaluate the association between patient-initiated repackaging of ART and viral suppression as well as describing types of ART drug resistance among a cohort of HIV-infected adults attending five infectious disease clinics in Northern Tanzania.
Methods

Study Design and Population
We used a cross-sectional study design to evaluate the association between patient-initiated repackaging of ART and viral suppression and ART drug resistance. The study population included HIV-infected adult patients attending five Care and Treatment Centers (CTC) in Northern Tanzania between January 2004 and May 2015. These CTCs offer treatment according to the Tanzanian Ministry of Health Treatment Guidelines for the provision of ART. According to these guidelines, patients received a combination of tenofovir (TDF), lamivudine (3TC), and nevirapine (NVP) as first-line ART. Zidovudine (AZT) and efavirenz reused in place of TDF and NVP, respectively, depending upon toxicities and concurrent medications [10] . Patients initiated treatment if they had WHO clinical stage 3/4 or a CD4 count of \350 cells/mm 3 at baseline regardless of the clinical stage. Each patient was typically seen on a monthly basis and their prescriptions refilled. To be eligible for the study, participant had to consent to participate, be 18 years or older and on first line ART for a minimum of 6 months at the time of enrollment.
Data Collection
All patient data including demographics, type and quantity of medication used, opportunistic infections, self-reported adherence indicators (adherent = fewer than two missed days per month/non-adherent = 2 or more missed days per month), and laboratory values are routinely collected on standardized forms, and entered into a database designed and funded by the Tanzanian National AIDS Control Program (NACP) in collaboration with Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). We utilized this database for this study and for missing data, manual data abstraction was performed by the study team from patient's medical records. For the purpose of this study, additional data was collected on face-to-face interview. After obtaining informed consent, standardized questionnaires translated into Kiswahili were administered to participating patients by trained research nurses. The questionnaire captured patient repackaging behaviors. Specifically patients were asked if they repackage ART, what they discarded (medication box, medication bottle, packet insert).Furthermore, open ended question was administered to ascertain reasons for repackaging and later categorized. Blood samples were collected from all participants for viral load testing at Biotechnology Laboratory and resistance testing at the National Health Laboratory Quality And Training Centre (NHL-AATC). The Biotechnology Laboratory has participated in the ACTG Virology Quality Assurance Program for RNA measurement and UKNEQAS for flow cytometry quality assurance. Plasma samples were assayed for the presence of HIV RNA using the Roche Amplicor assay, version 1.5 (Roche Molecular Systems), with a lower limit of detection of 100 copies/mL. To describe type of ART resistance mutations, genotyping was attempted for patients with viral load [1000 c/ml. For those that were successfully genotyped, the presence of one or more major resistance mutations were ascertained. Key mutations were identified according to the March 2015 revision of the Stanford HIV drug resistance Mutations in HIV document [11] .
Definition of Variables
The primary outcome was viral suppression at the time of interview. Plasma HIV RNA level is \400 c/ml was defined as suppressed and plasma HIV RNA level is C400 c/ml not suppressed. We chose a cut off of 400 c/ml as opposed to the WHO recommended cut off in resource limited settings for two reasons. First, it has been used extensively in resource limited settings [9, [12] [13] [14] . Second, resistance mutations can develop even at low viral replication [15] . Exposure of interest was patient-initiated repackaging of ART. We defined patient initiated repackaging as removal of tablets from their bottles or pill bottles from their original boxes and/or discarding inserts including prescription descriptions. For patient-initiated behavior, participants were asked ''Do you repackage your ART? Follow up question was asked for those who reported repackaging; ''In the past 3 months, have you repackaged your ART''. Patient initiated repackaging was then categorized as binary variable; 'yes' if participant has been repackaging ART for the past 3 months and no if participant did not repackage. Other variables were evaluated including age, gender, duration on first-line ART, treatment sites, marital status, education, adherence to ART and CD4 cell count at the time of the interview.
Analysis
Our primary objective was to assess whether patient-initiated repackaging of ART was associated with failure to achieve viral suppression. The secondary objective was to describe types of ART resistance mutations. Frequencies of categorical variables were calculated as the proportions of patients sampled. Multivariate binomial regression model was used to assess the association between patient-initiated repackaging of ART and failure to achieve viral suppression. Bivariate binomial regression models were used to assess for potential confounders. All biologically plausible variables and those that changed the estimate by 20% on bivariable analyses were included in the final multivariate model. All associations were presented as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Estimates whose CIs excluded 1 were considered statistically significant.
Results
Survey questionnaires were administered to 450 HIV-infected patients receiving treatment between January 2004 and May 2015. Most were female (302, 67.1%), the majority were between 30 and 55 years old (332; 73.8%), had less than a primary school education (364; 80.1%), and 204 (45.5%) were either divorced/separated or widowed; ( Table 1) . Majority of the patients came from Mawenzi Regional Hospital (223; 49.5%). Approximately half of patients had been on first-line ART for longer than 5 years (236; 52.4%), and most patients were not aware that future treatment options were limited (301; 66.9%). Two hundred fifty-nine (57.6%) had plasma HIV RNA levels \400 copies/mL, and the most recent CD4 ? cell count was less than 350 c/mm 3 for 275 participants (61.1%).
Virological Failure and Association
One hundred and ninety-one patients (43%) failed to achieve viral suppression. Patients who reported to be repackaging their ART medications were more likely to fail in achieving viral suppression compared to those who did not repackage their medications [Odds ratio (OR), 1.8; 95% CI 1.2-2.6] ( Table 2 ). In bivariable analysis compared to male patients, female patients were less likely to not achieved viral suppression (OR 0.7; 95% CI 0.5-1.0). Other significant factors associated with failure in achieving viral suppression included, being aware on limited availability of future treatment options (OR 0.7; 95% CI 0.4-1.0) and being adherent to ART (OR 0.4; 95% CI 0.3-0.6). After adjusting for age, gender, education, marital status, CD4 cell count, duration on treatment, adherence to ART, awareness of limited treatment options and CTC sites, patient-initiated repackaging of ART continued to be associated with failure in achieving viral suppression (aOR 2.2; 95% CI 1.4-3.3) ( Table 2) . Several other factors that were associated with failure in achieving viral suppression on multivariate analysis included, CTC site (Mawenzi vs KCMC; aOR 1.9; 95% CI 1.1-3.6), being aware on limited availability of future treatment options (aOR 0.6; 95% CI 0.3-0.9) and adherence to ART (aOR 0.6; 95% CI 0.4-0.8).
ART Adherence and Patient Initiated Repackaging
Patient initiated repackaging of ART was associated with self-reported adherence to ART with those individuals reported to be adherent to ART being less likely to report repackaging (OR 0.3, 95% CI(0.2-0.4).
Antiretroviral Drug Resistance Mutations and HIV Subtypes
Among the 191 subjects with plasma HIV RNA levels [400 copies/mL, 48 (25%) had plasma HIV RNA levels C1000 copies/mL and had sequencing of their isolates attempted. Of these 48 subjects, 44 (91.7%) had successful HIV genotyping in which 11 subjects (25.0%) were infected with HIV type 1 subtype A, 8 (18.2%) were infected with HIV type 1 subtype C, 8 (18.2%) were infected with HIV type 1 subtype D and 17 (38.6%) were infected with circulating recombinant forms CRF01_AE. Of the 44 subjects, 35 (79.5%) had isolates with at least one major resistance mutations while nine had wild type virus. Two subjects had virus with only 1 major antiretroviral drug resistance mutation; in both cases, these were non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated mutations (K103 N in one and E138A in the other) ( Table 3) . One subject had two major resistance mutations, and these were one nucleoside reverse transcriptase inhibitor (NRTI)-associated mutation (M184 V) and the other NNRTI-associated mutations (K103 N). The remaining 32 (91.4%) patients had three or more major NRTI-and/or NNRTI-associated mutations. Of those who had three or more major resistance mutations, two had minor PI-associated mutations and these were K20KM, T74ST and L33F. On bivariable analysis patient-initiated repackaging of ART medications was marginally associated with resistance mutations (OR 1.2; 95% CI 0.9-1.4).
Discussion
We demonstrated high prevalence of patient-initiated repackaging of ART with 43.8% of the interviewed participants reporting to have repackaged their drugs. Failure to achieve viral suppression was also high with 42.4% of participants having plasma HIV RNA levels C400 copies/ m/L. The high level of participants who failed to achieve viral suppression in this population may be due to the different risk factors observed; for example, over half of the study participants had adherence less than 95% and two-thirds weren't aware that future ART treatment options are limited. Among those who reported repackaging, a quarter reported stigma being the main reason for repackaging. Moreover, about 70% of the study participants were on treatment for more than 3 years, as previously described, adherence to ART wanes with time, less adherent for those on treatment over a long time [16, 17] .
The main strengths of this study are that, to our knowledge, it is the first study that assesses the association between patient-initiated repackaging of ART medication and viral suppression. We found that patient-initiated repackaging of ART was associated with failure in achieving viral suppression with those repackaging their medications having an increased likelihood of not being suppressed. It is likely that patients who repackage their medications would have experienced HIV-associated stigma and thereby were less likely to take their medications as prescribed or even failing to attend clinic regularly for prescription refill. In areas where HIV is highly stigmatized such as in resource limited settings, repackaging of ART becomes an alternative way of coping with stigma as repackaged medications are hardly identifiable by others as HIV medicines [18] [19] [20] . The importance of HIV-associated stigma has been extensively documented and has shown to negatively impact HIV care and treatment [21] [22] [23] . As Table 2 Crude and adjusted risk factors of failure to achieve viral suppression to among HIV-infected adults receiving first-line art at five care and treatment centers in Kilimanjaro Region, Moshi, Tanzania Lack of knowledge on limited availability of future treatment options was associated with failure to achieve viral suppression. A recent study reported that patients who were aware of their ART line of treatment and who were also informed of limited future treatment options were more likely to be adherent to ART [24] . It is possible that association of knowledge and failure to achieve viral suppression is mediated by adherence to ART. Evaluation of patient-initiated repackaging and self-reported adherence revealed that those who were repackaging tended to be less likely to be adherent. Implementing strategies to reduce HIV-associated stigma in order to improve adherence and reduce the development of resistance mutations is critical.
We demonstrated a high level of resistance mutations with 35 of 44 patients with HIV RNA C1000 copies/mL having at least one or more major resistance mutations. Although majority had NRTI-and NNRTI-associated resistance mutations, a few had minor PI-associated resistance mutations. PI is the final salvage regimen in many parts of resource limited settings [25, 26] . Given limited availability of future treatment options in resource-limited settings, such an observation serves as a wakeup call to health care workers in these settings. Of note is the high proportion of patients with circulating recombinant forms. Approximately 39% of the study participants had circulating CRF01_AE. These circulating recombinants have been documented to be associated with negative outcomes such as high viral load [18] , shorter patient survival [19] and faster disease progression to AIDS [20] .
Although we were able to show association between patient-initiated repackaging of ART and failed viral suppression, our study is not without limitations. This association was evaluated using a cross-sectional study design, thereby limiting our ability to establish temporal relationship. In addition, the adherence assessments relied on selfreports, and the latter is subject to biases including recall bias [25, 27] . However, self-reported adherence has been used extensively and noted to be associated with clinical outcomes such as virological failure [9, 28, 29] . Since approximately 70% of the study participants had been on treatment for more than 3 years, the study consisted of a stable population and likely that ART repackaging was under estimated and hence limiting generalizability. An ideal assessment of ART repackaging would involve new participants who have been on treatment for duration of less than 1 year. Newly diagnosed HIV patients are likely to be highly stigmatized and repackage ART compared to patients who have been on ART over a long duration. In addition, repackaging might have changed with time. In 2004, patients used to receive multiple drugs per day as compared to 2010's where patients receive single tablet per day. Differences in the amount of drugs dispensed might have altered repackaging behaviors. Furthermore, correlates of stigma were not measured and this may impair our ability to ascertain effects of stigma and repackaging of ART. Despite the limitations, the use of reliable laboratory measures for viral load and testing for drug resistance make this study stronger.
Conclusion
The study reports that patient-initiated repackaging of ART medications is important predictor of viral suppression; patients who repackaged their medications were more likely to not being suppressed. It is critical for the health care providers in resource-limited settings to continuously provide information on the importance of keeping drugs within PI protease inhibitor, NRTI nucleoside reverse-transcriptase inhibitor, NNRTI nonnucleoside reverse-transcriptase inhibitor AIDS Behav their original packaging. Keeping medications in original containers maintains drug's effectiveness, reduces the likelihood of mixing drugs and thereby improving patient adherence, a core component in improving viral suppression and preventing ART drug resistance. Further studies on the effect of patient initiated repackaging on ART efficacy are needed in order to better understand the negative effects of repackaging and maximize benefits of ART.
